COMP <GO>
KNSA vs PRAX // ALTMAN Z-SCORE & DEBT/EQUITY
Kiniksa Pharmaceuticals International plc (Class A) (NASDAQ) VS. Praxis Precision Medicines Inc. (NASDAQ) • 15-METRIC TALLY: KNSA 6
— PRAX 3
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: PRAX
LAST: $97.56 (+2.50%) • MKT CAP: $7.67B
balance-sheet
24.45
LAST: $288.62 (+1.10%) • MKT CAP: $8.06B
balance-sheet
26.00
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (KNSA VS. PRAX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | KNSA | PRAX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 88.50% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 9.90% | -35.00% | +44.90 | KNSA | /roic <GO> |
| EV/EBITDA & P/E Valuation | 95.0x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 1.78% | -3.09% | +4.87 | KNSA | /fcf-yield <GO> |
| Operating Margin | 11.40% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | 8.70% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | 60.10% | 8.80% | +51.30 | KNSA | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 24.45 | 26.00 | -1.55 | PRAX | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 5/9 | +4.00 | KNSA | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 67.4 | 56.3 | +11.10 | KNSA | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.11 | 0.91 | +0.20 | KNSA | /macro-sensitivity <GO> |
| Forward P/E Multiple | 109.1x | 33.0x | +76.10 | PRAX | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $7.67B | $8.06B | -$392.8M | PRAX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | KNSA REV | PRAX REV | KNSA GROSS % | PRAX GROSS % | KNSA FCF | PRAX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $677.6M | $0 | 88.5% | — | $136.4M | -$249.1M |
| FY 2024 | $423.2M | $8.6M | 85.6% | — | $25.4M | -$131.8M |
| FY 2023 | $270.3M | $2.4M | — | — | $1.1M | -$111.2M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
KNSA // BETA 1.11
PRAX // BETA 0.91